CompletedPhase 2NCT04581629
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
Studying Autosomal dominant hypocalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Principal Investigator
- Calcilytix Medical DirectorCalcilytix Therapeutics, Inc., a BridgeBio company
- Intervention
- Encaleret(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2020 – 2023
Study locations (1)
- National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04581629 on ClinicalTrials.govOther trials for Autosomal dominant hypocalcemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07428057Postoperative Hypocalcemia After ThyroidectomyMinia University
- RECRUITINGPHASE2, PHASE3NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGPHASE3NCT05680818Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Calcilytix Therapeutics, Inc., a BridgeBio company
- ACTIVE NOT RECRUITINGNCT05227287ADH1 and ADH2 Disease Monitoring Study (DMS)Calcilytix Therapeutics, Inc., a BridgeBio company